Growth fraction (Ki-67 antibody) determination in early-stage breast carcinoma: histologic, clinical and prognostic correlations

G. Gasparini, F. Pozza, P. Bevilacqua, S. Meli, P. Boracchi, M. Reitano, G. Santini, E. Marubini, J. R C Sainsbury

Research output: Contribution to journalArticlepeer-review

Abstract

Proliferative indices were measured on a prospective series of 165 patients with stage I and II breast cancer using an immunocytochemical determination of Growth Fraction (GF) with the Ki-67 monoclonal antibody and S-phase fraction by flow cytometry. GF score ranged from 1% to 80% with a median value of 7.5% and was significantly associated with aneuploidy (p=0.01), axillary node involvement (p=0.016) and histologic grade (p=0.0001). A weak association was observed between the two markers of cell kinetics, particulary among diploid tumours. After a median follow-up of 3 years univariate analysis showed that patients with tumours with low GF had a significantly better relapse-free survival when compared to those with high GF (p=0.0027). At 3 years there was no significant difference in survival between the two groups. A multivariate analysis on relapse free survival, performed in 122 comparable patients, showed that GF was a significant independent predictive factor (p=0.04). GF is an easy and reliable method for assessing cell kinetics in breast cancer and it is correlated with prognosis.

Original languageEnglish
Pages (from-to)92-99
Number of pages8
JournalBreast
Volume1
Issue number2
DOIs
Publication statusPublished - 1992

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Fingerprint

Dive into the research topics of 'Growth fraction (Ki-67 antibody) determination in early-stage breast carcinoma: histologic, clinical and prognostic correlations'. Together they form a unique fingerprint.

Cite this